We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




New Delivery Technique Hits Solid Tumors with Arsenic Trioxide

By LabMedica International staff writers
Posted on 26 Jul 2010
A new delivery mechanism has been developed that allows the classic chemotherapeutic agent arsenic trioxide to kill solid tumors effectively.

Conventional wisdom has been that arsenic trioxide, which works against some types of leukemia, cannot be used against solid tumors because of its extreme toxicity and rapid excretion from the body.

However, in a paper published in the July 2010 issue of the journal Clinical Cancer Research investigators at Northwestern University (Evanston, IL, USA) described a method for encapsulating arsenic trioxide inside nanoparticle-sized liposomal vesicles to form what they called "nanobins.” Efficacy of treatment with arsenic trioxide nanobins was evaluated in breast cancer-cell cultures and in a mouse model of human "triple-negative” breast cancer.

Results showed that while the nanobins were much less cytotoxic in vitro than free arsenic trioxide against the panel of human breast cancer-cell lines, they dramatically increased the therapeutic efficacy of arsenic trioxide in vivo in the mouse model of triple-negative breast cancer. More...
Reduced plasma clearance, enhanced tumor uptake, and induction of tumor cell apoptosis were observed following nanobin treatment. None of these effects was seen in animals treated with arsenic trioxide alone or with empty nanobins.

"Everyone said you cannot use arsenic for solid tumors,” said senior author Dr. Tom O'Halloran, professor of chemistry and biochemistry at Northwestern University. "That is because they did not deliver it the right way. This new technology delivered the drug directly to the tumor, maintained its stability, and shielded normal cells from the toxicity. That is huge. Once you fine-tune this, you could use what would otherwise be a lethal or highly toxic dose of the drug, because a good deal of it will be directly released in the tumor.”

Related Links:
Northwestern University




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Gold Member
Platelet Function Analyzer
PL-12
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: 123RF

Screening After Pneumococcal Disease May Reveal Undiagnosed Blood Cancer or Immune Disorders

Severe pneumococcal disease requiring hospitalization often presents as pneumonia, particularly in older adults and people with cancer or compromised immune function. Because M protein testing and antibody... Read more

Microbiology

view channel
Image Credit: 123RF

FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample

Respiratory tract infections can be difficult to distinguish at presentation because many cause overlapping, nonspecific symptoms and are initially grouped as influenza-like illnesses. Causes span a range... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.